TBPH Stock Analysis: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$16.87
0.01 (0.06%)
▲
5d:
+0.06%
30d:
-0.35%
90d:
+0.48%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TBPH shows positive signals but monitor for confirmation. Market pricing in 18.3% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: TBPH shows positive signals but monitor for confirmation. Market pricing in 18.3% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$19.79
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$12.29
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $16.87, which is considered fair relative to its 30-day fair value range of $16.79 to $17.10. From a valuation perspective, the stock is trading at a premium (Forward PE: 21.1) compared to its historical average (12.7). At these levels, the market is pricing in 18.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $16.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TBPH is in a uptrend. The price is currently testing key support at $16.81. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$16.79 -
$17.10
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.67)
- NEUTRAL: Trading at premium valuation - market expects 18.3% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$16.79 -
$17.10
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$16.81
Resistance Level
$16.92
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.09
Wall Street Target
$17.67
(+4.7%)
Revenue Growth (YoY)
15.0%
Profit Margin
104.3%
Valuation Premium vs History
+18.3% premium
PE vs Historical
21.1 vs 12.7
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+18.3%
(market-implied from PE analysis)
1-Year Target
$19.96
(+18%)
2-Year Target
$23.61
(+40%)
3-Year Target
$27.93
(+66%)
3-Yr Target (if PE normalizes)
(PE: 21→13)
PE COMPRESSION
$16.82
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.1, Growth: 281.0%)
$56.94
(+238%)
Base:
(SPY PE: 20.7, Growth: 281.0%)
$55.97
(+232%)
Bear:
(PE: 12.7, Growth: 281.0%)
$34.29
(+103%)
📈
Valuation based on Current Earnings
Trailing PE: 7.56 | Current EPS (TTM): $2.23
Bull Case
$9.27
(-45%)
Analyst growth -50.0%, PE expands to 8.3
Base Case
$8.43
(-50%)
Market implied -50.0%, PE stable at 7.6
Bear Case
$11.46
(-32%)
Severe decline -20.0%, PE contracts to 6.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 04, 2026 3:39 AM ET
Data refreshes hourly during market hours. Next update: 4:39 AM
Data refreshes hourly during market hours. Next update: 4:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rhonda Farnum
SELL
31067 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
